Breast cancer is a highly heterogeneous disease and our data cannot unequivocally tell us whether the TIMP‐1/CD74 interaction is of pathophysiological relevance regarding tumor progression or response to treatment. This evidence concerns the gene CD74 and breast carcinoma.